On the afternoon of September 19, Ding Jian, academician of the Chinese Academy of Engineering, Zhang Haiyan and Huang Chenggang, researchers of the Chinese Academy of Sciences Shanghai Institute of Materia Medica, and a group of three came to Zhejiang Cheng Yi Pharmaceutical Co., Ltd. to give special technical guidance to the company's "research and innovation projects".
The person in charge of the company gave a detailed introduction to the "nervonic acid" project being developed. At present, the company's research institute has increased the purity of the drug substance from 85% to 99%. At present, the trial produced "Nerve Acid Soft Capsule" has achieved 99% of the purity of nervonic acid and 99% of the purity of DHA, which has achieved preliminary results.
Academician Ding Jian, Researcher Zhang Haiyan, and Researcher Huang Chenggang listened to the report and consulted relevant materials to analyze and study the company's research and innovation work. They believe that this is a critical period for Cheng Yi Pharmaceutical to make a significant progress from the "generic drug stage" to the "innovative drug stage" and is a pioneering move. At the same time, many valuable opinions and suggestions were put forward to clarify the company's thinking and indicate direction.
Academician Ding Jian said that on his second visit to Dongtou, he saw significant changes in Cheng Yi pharmaceutical industry. Since the outbreak of the epidemic, many domestic enterprises have been greatly impacted, but Cheng Yi Pharmaceutical has been moving upwards, indicating that the products are excellent, the market is rigid, and the prospects will be very bright.